Genmab A/S (OTCMKTS:GNMSF) Stock Price Passes Above 50 Day Moving Average – Here’s What Happened

Genmab A/S (OTCMKTS:GNMSF)’s stock price passed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $300.31 and traded as high as $306.00. Genmab A/S shares last traded at $306.00, with a volume of 20 shares traded.

Genmab A/S Stock Up 0.3%

The company has a market capitalization of $20.22 billion, a P/E ratio of 15.36 and a beta of 0.93. The company has a 50-day moving average of $300.31 and a two-hundred day moving average of $247.94.

Genmab A/S (OTCMKTS:GNMSF) last posted its quarterly earnings results on Thursday, November 6th. The company reported $6.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.86 by $1.60. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%.The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1 billion.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.